While existing treatments for AUD and SUDs are often limited by regulatory restrictions and stigma, GLP-1RAs may benefit from their established approval for metabolic disorders
If weight regain exceeds five pounds and continues trending upward after four weeks, reassess your approach
Ro Offers Eli Lilly's Foundayo, the Newest GLP-1 Innovation Foundayo gives patients a new once daily pill option and expands Ros comprehensive weight loss formulary April 9, 2026 Ro, the leading direct-to-patient healthcare company, today announced eligible patients can now access Foundayo (orforglipron) Eli Lilly Companys newest oral GLP-1 innovation on the Ro platform, adding to Ros already comprehensive formulary of FDA-approved GLP-1s
These obesity medications, such as Glucagon Like Peptide-1 Receptor Agonists (GLP-1 RAs), have gained significant attention for their promising efficacy in achieving weight loss
Because actual numbers depend on your model, here's how to think about it in two buckets